tbuckley/cabot-search huggingface dataset:
Always a bridesmaid, never a bride: Committing to flu neuraminidase as a vaccine target
Authors: Cosette Schneider, Lynda Coughlan
Journal: Molecular Therapy (2023)

Influenza A viruses pose an ongoing threat due to their role in seasonal epidemics and the potential for the emergence of novel viruses from the animal reservoir. 1 Kerstetter L.J. Buckley S. Bliss C.M. Coughlan L. Adenoviral vectors as vaccines for emerging avian influenza viruses. Front. Immunol. 2020; 11607333https://doi.org/10.3389/fimmu.2020.607333 Crossref PubMed Scopus (20) Google Scholar Extensive efforts are being made to develop vaccines that elicit protection against multiple influenza virus antigens, as well as universal vaccines that confer broad protection against antigenically distinct seasonal and/or pandemic viruses. In order to achieve long-lived and cross-protective immunity, it is considered that combining distinct vaccine platforms in heterologous prime:boost regimens may be required. 2 Coughlan L. Palese P. Overcoming barriers in the path to a universal influenza virus vaccine. Cell Host Microbe. 2018; 24: 18-24https://doi.org/10.1016/j.chom.2018.06.016 Abstract Full Text Full Text PDF PubMed Scopus (59) Google Scholar
Re: Peter Fletcher, Marta De Santis, Simona Ippoliti, et al. Vector Prostate Biopsy: A Novel Magnetic Resonance Imaging/Ultrasound Image Fusion Transperineal Biopsy Technique Using Electromagnetic Needle Tracking Under Local Anaesthesia. Eur Urol 2023;83:249–56
Authors: Tianrui Feng, Miao Ren, Zhien Zhou
Journal: European Urology (2023)
Discovering Precise Temporal Patterns in Large-Scale Neural Recordings through Robust and Interpretable Time Warping
Authors: Alex H. Williams, Ben Poole, Niru Maheswaranathan, Ashesh K. Dhawale, Tucker Fisher, Christopher D. Wilson, David H. Brann, Eric M. Trautmann, Stephen Ryu, Roman Shusterman, Dmitry Rinberg, Bence P. Ölveczky, Krishna V. Shenoy, Surya Gangul
Journal: Neuron (2023)
Maintenance of GABAergic Activity by Neuregulin 1-ErbB4 in Amygdala for Fear Memory
Authors: Yisheng Lu, Xiang-Dong Sun, Feng-Qing Hou, Lin-Lin Bi, Dong-Min Yin, Fang Liu, Yong-Jun Chen, Jonathan C. Bean, Hui-Feng Jiao, Xihui Liu, Bao-Ming Li, Wen-Cheng Xiong, Tian-Ming Gao, Lin Mei
Journal: Neuron (2023)
Safety and immunogenicity of heterologous boosting with orally aerosolised or intramuscular Ad5-nCoV vaccine and homologous boosting with inactivated vaccines (BBIBP-CorV or CoronaVac) in children and adolescents: a randomised, open-label, parallel-controlled, non-inferiority, single-centre study
Authors: Tao Huang, Sheng Zhang, De-Fang Dai, Bu-Sen Wang, Lu Zhuang, Hai-Tao Huang, Zhong-Fang Wang, Jun-Shi Zhao, Qiu-Ping Li, Shi-Po Wu, Xue Wang, Wen-Dan Zhang, Zheng-Hao Zhao, Hao Li, Yan-Ping Zhang, Xiu-Liang Yang, Xin-Yang Jiang, Jin-Bo Gou, Li-Hua Hou, Li-Dong Gao, Zhi-Chun Feng
Journal: The Lancet Respiratory Medicine (2023)
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Authors: Frances A. Shepherd, Janet Dancey, Rodryg Ramlau, Karin Mattson, Richard Gralla, Mark O’Rourke, Nathan Levitan, Laurent Gressot, Mark Vincent, Ronald Burkes, Susan Coughlin, Yong Kim, Jocelyne Berille
Journal: Journal of Clinical Oncology (2023)

To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung cancer who had previously been treated with platinum-based chemotherapy. Secondary end points included assessment of response (docetaxel arm only), toxicity, and quality of life.
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy
Authors: Nasser Hanna, Frances A. Shepherd, Frank V. Fossella, Jose R. Pereira, Filippo De Marinis, Joachim von Pawel, Ulrich Gatzemeier, Thomas Chang Yao Tsao, Miklos Pless, Thomas Muller, Hong-Liang Lim, Christopher Desch, Klara Szondy, Radj Gervais, None Shaharyar, Christian Manegold, Sofia Paul, Paolo Paoletti, Lawrence Einhorn, Paul A. Bunn
Journal: Journal of Clinical Oncology (2023)

To compare the efficacy and toxicity of pemetrexed versus docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy.
Mass drug administration in neglected tropical diseases: beyond elimination
Authors: Kaliaperumal Karthikeyan
Journal: The Lancet Global Health (2023)

The impact of neglected tropical diseases on the socioeconomic and social wellbeing of individuals in low-income and middle-income countries is enormous. These neglected tropical diseases account for around 14·5 million disability-adjusted life years, with substantial variation among tropical and non-tropical countries and high-resource and low-resource regions.1 Working in a resource-poor setting and managing these disorders is a challenge for practitioners. Outpatient units are flooded with patients with scabies, helminthiasis, and other neglected tropical diseases.
Eradicating<i>Helicobacter pylori</i>via<sup>13</sup>C-urea breath screening to prevent gastric cancer in indigenous communities: a population-based study and development of a family index-case method
Authors: Wei-Yi Lei, Jian-Yu Lee, Shu-Ling Chuang, Ming-Jong Bair, Chien-Lin Chen, Jeng-Yih Wu, Deng-Chyang Wu, Felice Tien O’Donnell, Hui-Wen Tien, Yi-Ru Chen, Tsung-Hsien Chiang, Yu-Hsin Hsu, Tsui-Hsia Hsu, Pei-Chun Hsieh, Li-Ju Lin, Shu-Li Chia, Chao-Chun Wu, Yi-Maun Subeq, Shu-Hui Wen, Hsiu-Chun Chang, Yu-Wen Lin, Kuo-Ping Sun, Chia-Hsiang Chu, Ming-Shiang Wu, David Y Graham, Hsiu-Hsi Chen, Yi-Chia Lee
Journal: Gut (2023)

Objective Screening and eradication of Helicobacter pylori help reduce disparities in the incidence of gastric cancer. We aimed to evaluate its acceptability and feasibility in the indigenous communities and develop a family index-case method to roll out this programme. Design We enrolled residents aged 20–60 years from Taiwanese indigenous communities to receive a course of test, treat, retest and re-treat initial treatment failures with the 13 C-urea breath tests and four-drug antibiotic treatments. We also invited the family members of a participant (constituting an index case) to join the programme and evaluated whether the infection rate would be higher in the positive index cases. Results Between 24 September 2018 and 31 December 2021, 15 057 participants (8852 indigenous and 6205 non-indigenous) were enrolled, with a participation rate of 80.0% (15 057 of 18 821 invitees). The positivity rate was 44.1% (95% CI 43.3% to 44.9%). In the proof-of-concept study with 72 indigenous families (258 participants), family members of a positive index case had 1.98 times (95% CI 1.03 to 3.80) higher prevalence of H. pylori than those of a negative index case. The results were replicated in the mass screening setting (1.95 times, 95% CI 1.61 to 2.36) when 1115 indigenous and 555 non-indigenous families were included (4157 participants). Of the 6643 testing positive, 5493 (82.6%) received treatment. According to intention-to-treat and per-protocol analyses, the eradication rates were 91.7% (89.1% to 94.3%) and 92.1% (89.2% to 95.0%), respectively, after one to two courses of treatment. The rate of adverse effects leading to treatment discontinuation was low at 1.2% (0.9% to 1.5%). Conclusion A high participation rate, a high eradication rate of H. pylori and an efficient rollout method indicate that a primary prevention strategy is acceptable and feasible in indigenous communities. Trial registration number NCT03900910 .
Distinct immune modulatory roles of regulatory T cells in gut versus joint inflammation in TNF-driven spondyloarthritis
Authors: Koen Venken, Matthias Jarlborg, Tine Decruy, Céline Mortier, Carolien Vlieghe, Elisabeth Gilis, Ann-Sophie De Craemer, Julie Coudenys, Isabelle Cambré, Devan Fleury, Alexander Klimowicz, Filip Van den Bosch, Anne Hoorens, Triana Lobaton, Sytze de Roock, Tim Sparwasser, Gerald Nabozny, Peggy Jacques, Dirk Elewaut
Journal: Annals of the Rheumatic Diseases (2023)

Gut and joint inflammation commonly co-occur in spondyloarthritis (SpA) which strongly restricts therapeutic modalities. The immunobiology underlying differences between gut and joint immune regulation, however, is poorly understood. We therefore assessed the immunoregulatory role of CD4+FOXP3+ regulatory T (Treg) cells in a model of Crohn's-like ileitis and concomitant arthritis.RNA-sequencing and flow cytometry was performed on inflamed gut and joint samples and tissue-derived Tregs from tumour necrosis factor (TNF)∆ARE mice. In situ hybridisation of TNF and its receptors (TNFR) was applied to human SpA gut biopsies. Soluble TNFR (sTNFR) levels were measured in serum of mice and patients with SpA and controls. Treg function was explored by in vitro cocultures and in vivo by conditional Treg depletion.Chronic TNF exposure induced several TNF superfamily (TNFSF) members (4-1BBL, TWEAK and TRAIL) in synovium and ileum in a site-specific manner. Elevated TNFR2 messenger RNA levels were noted in TNF∆ARE/+ mice leading to increased sTNFR2 release. Likewise, sTNFR2 levels were higher in patients with SpA with gut inflammation and distinct from inflammatory and healthy controls. Tregs accumulated at both gut and joints of TNF∆ARE mice, yet their TNFR2 expression and suppressive function was significantly lower in synovium versus ileum. In line herewith, synovial and intestinal Tregs displayed a distinct transcriptional profile with tissue-restricted TNFSF receptor and p38MAPK gene expression.These data point to profound differences in immune-regulation between Crohn's ileitis and peripheral arthritis. Whereas Tregs control ileitis they fail to dampen joint inflammation. Synovial resident Tregs are particularly maladapted to chronic TNF exposure.
Technical performance and diagnostic yield of motorised spiral enteroscopy compared with single-balloon enteroscopy in suspected Crohn’s disease: a randomised controlled, open-label study (the MOTOR-CD trial)
Authors: Partha Pal, Mohan Ramchandani, Rupa Banerjee, Piyush Viswakarma, Aniruddha Pratap Singh, Manohar Reddy, Hardik Rughwani, Rajendra Patel, Anuradha Sekaran, Swathi Kanaganti, Santosh Darisetty, Zaheer Nabi, Jagadish Singh, Rajesh Gupta, Sundeep Lakhtakia, Rebala Pradeep, G Venkat Rao, Manu Tandan, D Nageshwar Reddy
Journal: Gut (2023)

Recent studies have shown that motorised spiral enteroscopy (MSE) enables deeper and total small bowel evaluation compared with single-balloon enteroscopy (SBE) in suspected Crohn's disease (CD) when analysed per procedure. However, no randomised controlled study has compared bidirectional MSE with bidirectional SBE in suspected CD.Patients with suspected CD requiring small bowel enteroscopy were randomly assigned to either SBE or MSE between May 2022 and September 2022 in a high volume tertiary centre. Bidirectional enteroscopy was done if intended lesion could not be reached on unidirectional study. Comparison was made with regard to technical success (ability to reach lesion), diagnostic yield, depth of maximal insertion (DMI), procedure time and total enteroscopy rates. Depth:time ratio was calculated to avoid confounding for the location of lesion.Among 125 suspected patients with CD (28% female, 18-65 years, median 41 years), 62 and 63 underwent MSE and SBE, respectively. The overall technical success (98.4 %: MSE, 90.5 %: SBE; p=0.11), diagnostic yield (95.2%: MSE; 87.3%: SBE, p=0.2) and procedure time were not significantly different. However, MSE appeared to have higher technical success (96.8% vs 80.7%, p=0.08) in deeper small bowel (distal jejunum/proximal ileum) with higher DMI, higher depth:time ratio and total enteroscopy rates when attempted (77.8% vs 11.1%, p=0.0007). Both the modalities were safe although minor adverse events were more common with MSE.MSE and SBE have comparable technical success and diagnostic yield for small bowel evaluation in suspected CD. MSE scores over SBE with regard to deeper small bowel evaluation with complete small bowel coverage and higher depth of insertion in a shorter time.NCT05363930.
The incidence of perioperative lymphatic complications after radical hysterectomy and pelvic lymphadenectomy between robotic and laparoscopic approach : a systemic review and meta-analysis
Authors: Jong Ha Hwang, Bo Wook Kim
Journal: International Journal of Surgery (2023)

Background: Although many studies have reported perioperative complications after radical hysterectomy and pelvic lymph node dissection using robotic and laparoscopic approaches, the risk of perioperative lymphatic complications has not been well identified. The aim of this meta-analysis is to compare the risks of perioperative lymphatic complications after robotic radical hysterectomy and lymph node dissection (RRHND) with laparoscopic radical hysterectomy and lymph node dissection (LRHND) for early uterine cervical cancer. Materials and methods: We searched the PubMed, Cochrane Library, Web of Science, ScienceDirect, and Google Scholar databases for studies published up to July 2022 comparing perioperative lymphatic complications after RRHND and LRHND while treating early uterine cervical cancer. Related articles and bibliographies of relevant studies were also checked. Two reviewers independently performed the data extraction. Results: A total of 19 eligible clinical trials (15 retrospective studies and 4 prospective studies) comprising 3,079 patients were included in this analysis. Only 107 patients (3.48%) had perioperative lymphatic complications, of which the most common was lymphedema (n=57, 1.85%), followed by symptomatic lymphocele (n=30, 0.97%), and lymphorrhea (n=15, 0.49%). When all studies were pooled, the odds ratio (OR) for the risk of any lymphatic complication after RRHND compared with LRHND was 1.27 (95% confidence interval: 0.86-1.89; P =0.230). In the subgroup analysis, study quality, country of research, and publication year were not associated with perioperative lymphatic complications. Conclusion: A meta-analysis of the available current literature suggests that RRHND is not superior to LRHND in terms of perioperative lymphatic complications.
Screening for 3 Genetic Conditions Is Cost-effective in Younger People
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Approved and investigational fluorescent optical imaging agents for disease detection in surgery
Authors: Sonia Rehman, Paul M. Brennan, Annamaria Lilienkampf, Mark Bradley
Journal: International Journal of Surgery (2023)

Fluorescent optical imaging is becoming an increasingly attractive imaging tool that physicians can utilise as it can detect previously 'unseen' changes in tissue at a cellular level that are consistent with disease. This is possible using a range of fluorescently labelled imaging agents that, once excited by specific wavelengths of light, can illuminate damaged and diseased tissues. For surgeons, such agents can permit dynamic, intraoperative imaging providing a real-time guide as they resect diseased tissue.
Use of the European Organisation for Research and Treatment of Cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development
Authors: K. Forde, K. Cocks, J. R. Wells, I. McMillan, C. Kyriakou
Journal: Blood Cancer Journal (2023)

Abstract The European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was developed in 1996 to assess health-related quality of life (HRQoL) in patients with multiple myeloma. Since its development new therapies have prolonged survival in patients with myeloma and new combination agents are likely to impact HRQoL outcomes and its measurement. The aim of this review was to explore the use of the QLQ-MY20 and reported methodological issues. An electronic database search was conducted (1996-June 2020) to identify clinical studies/research that used the QLQ-MY20 or assessed its psychometric properties. Data were extracted from full-text publications/conference abstracts and checked by a second rater. The search returned 65 clinical and 9 psychometric validation studies. The QLQ-MY20 was used in interventional ( n = 21, 32%) and observational ( n = 44, 68%) studies and the publication of QLQ-MY20 data in clinical trials increased over time. Clinical studies commonly included relapsed patients with myeloma patients ( n = 15, 68%) and assessed a range of combinations therapies. QLQ-MY20 subscales (disease symptoms [DS], side effects of treatment [SE], future perspectives [FP], body image [BI]) were defined as secondary ( n = 12, 55%) or exploratory ( n = 7, 32%) trial endpoints, particularly DS ( n = 16, 72%) and SE ( n = 16, 72%). Validation articles demonstrated that all domains performed well regarding internal consistency reliability (&gt;0.7), test-reset reliability (intraclass correlation coefficient &gt; =0.85), internal and external convergent and discriminant validity. Four articles reported a high percentage of ceiling effects in the BI subscale; all other subscales performed well regarding floor and ceiling effects. The EORTC QLQ-MY20 remains a widely used and psychometrically robust instrument. While no specific problems were identified from the published literature, qualitative interviews are ongoing to ensure new concepts and side effects are included that may arise from patients receiving novel treatments or from longer survival with multiple lines of treatment.
ChatGPT/GPT-4: enabling a new era of surgical oncology
Authors: Kunming Cheng, Haiyang Wu, Cheng Li
Journal: International Journal of Surgery (2023)

aDepartment of Intensive Care Unit, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China bDepartment of Graduate School, Tianjin Medical University, Tianjin, China cClinical College of Neurology, Neurosurgery and Neurorehabilitation, Tianjin Medical University, Tianjin, China dDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA eDepartment of Orthopaedic Surgery, Beijing Jishuitan Hospital, Fourth Clinical College of Peking University, Beijing, China Kunming Cheng, Haiyang Wu, These authors have contributed equally to this work. The data underlying this article will be shared by the corresponding author on reasonable request. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Duke University, Durham, NC UNITED STATES. E-mail address: [email protected] (H. Wu). *Corresponding author. Address: . E-mail address: [email protected] (C. Li). This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0/
Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression
Authors: Jason V Evans, Shankar Suman, Mounika Uttam L Goruganthu, Elena E Tchekneva, Shuxiao Guan, Rajeswara Rao Arasada, Anneliese Antonucci, Longzhu Piao, Irina Ilgisonis, Andrey A Bobko, Benoit Driesschaert, Roman V Uzhachenko, Rebecca Hoyd, Alexandre Samouilov, Joseph Amann, Ruohan Wu, Lai Wei, Aaditya Pallerla, Sergey V Ryzhov, Igor Feoktistov, Kyungho P Park, Takefumi Kikuchi, Julio Castro, Alla V Ivanova, Thanigaivelan Kanagasabai, Dwight H Owen, Daniel J Spakowicz, Jay L Zweier, David P Carbone, Sergey V Novitskiy, Valery V Khramtsov, Anil Shanker, Mikhail M Dikov
Journal: JNCI Journal of the National Cancer Institute (2023)

Abstract Background We investigated the role of A2B-adenosine receptor in regulating immunosuppressive metabolic stress in the tumor microenvironment. Novel A2B-adenosine receptor antagonist PBF-1129 was tested for antitumor activity in mice and evaluated for safety and immunologic efficacy in a phase I clinical trial of patients with non-small cell lung cancer. Methods The antitumor efficacy of A2B-adenosine receptor antagonists and their impact on the metabolic and immune tumor microenvironment were evaluated in lung, melanoma, colon, breast, and epidermal growth factor receptor–inducible transgenic cancer models. Employing electron paramagnetic resonance, we assessed changes in tumor microenvironment metabolic parameters, including pO2, pH, and inorganic phosphate, during tumor growth and evaluated the immunologic effects of PBF-1129, including its pharmacokinetics, safety, and toxicity, in patients with non-small cell lung cancer. Results Levels of metabolic stress correlated with tumor growth, metastasis, and immunosuppression. Tumor interstitial inorganic phosphate emerged as a correlative and cumulative measure of tumor microenvironment stress and immunosuppression. A2B-adenosine receptor inhibition alleviated metabolic stress, downregulated expression of adenosine-generating ectonucleotidases, increased expression of adenosine deaminase, decreased tumor growth and metastasis, increased interferon γ production, and enhanced the efficacy of antitumor therapies following combination regimens in animal models (anti–programmed cell death 1 protein vs anti–programmed cell death 1 protein plus PBF-1129 treatment hazard ratio = 11.74 [95% confidence interval = 3.35 to 41.13], n = 10, P &amp;lt; .001, 2-sided F test). In patients with non-small cell lung cancer, PBF-1129 was well tolerated, with no dose-limiting toxicities; demonstrated pharmacologic efficacy; modulated the adenosine generation system; and improved antitumor immunity. Conclusions Data identify A2B-adenosine receptor as a valuable therapeutic target to modify metabolic and immune tumor microenvironment to reduce immunosuppression, enhance the efficacy of immunotherapies, and support clinical application of PBF-1129 in combination therapies.
Right Ventricular Sarcomere Contractile Depression and the Role of Thick Filament Activation in Human Heart Failure With Pulmonary Hypertension
Authors: Vivek Jani, M. Imran Aslam, Axel J. Fenwick, Weikang Ma, Henry Gong, Gregory Milburn, Devin Nissen, Ilton M. Cubero Salazar, Olivia Hanselman, Monica Mukherjee, Marc K. Halushka, Kenneth B. Margulies, Kenneth S. Campbell, Thomas C. Irving, David A. Kass, Steven Hsu
Journal: Circulation (2023)

Right ventricular (RV) contractile dysfunction commonly occurs and worsens outcomes in patients with heart failure with reduced ejection fraction and pulmonary hypertension (HFrEF-PH). However, such dysfunction often goes undetected by standard clinical RV indices, raising concerns that they may not reflect aspects of underlying myocyte dysfunction. We thus sought to characterize RV myocyte contractile depression in HFrEF-PH, identify those components reflected by clinical RV indices, and uncover underlying biophysical mechanisms.